STC. UNM Patent applications |
Patent application number | Title | Published |
20160128947 | BIOADHESIVE FILMS FOR LOCAL AND/OR SYSTEMIC DELIVERY - Bioadhesive films suitable for topical, local, and systemic drug delivery and methods for making the same. The films may incorporate one or more polymeric layers that enable delivery of a specific, desired dosage, to a specific, desired location over a specific, desired time period. | 05-12-2016 |
20150293004 | Viscosity measuring method - A method for measuring the average viscosity of a test fluid uses calibrated magnetic nanoparticles, with certain chosen hydrodynamic diameters and actual lateral dimensions (e.g. diameters), that are mixed into a small volume of the test fluid and a single magnetic relaxation curve measurement to provide data for viscosity determination. The distribution of hydrodynamic particle sizes of an ensemble of magnetic nanoparticles that are magnetically blocked at room temperature can be determined. Modifications of the method can be used to determine the distribution of viscosities in a complex fluid at the sub-microscopic level providing a novel type of viscosity measurement. | 10-15-2015 |
20150268926 | SYSTEM AND METHODS FOR SIMULATING REAL-TIME MULTISENSORY OUTPUT - The invention is directed to a system and methods allowing a user to interact with one or more data applications—including for example, games, music, music composition and tactile stimulation—to simulate real-time multisensory output. The invention includes a music program, a music texture program and a simulation program. | 09-24-2015 |
20150050292 | Detection, prevention, and treatment of Anthrax and other infectious diseases - Compositions and methods for the detection, prevention, or treatment of anthrax or other infectious diseases. In one aspect, the present invention provides methods for immunizing humans or animals against | 02-19-2015 |
20140322166 | GENE EXPRESSION SIGNATURES FOR DETECTION OF UNDERLYING PHILADELPHIA CHROMOSOME-LIKE (PH-LIKE) EVENTS AND THERAPEUTIC TARGETING IN LEUKEMIA - The invention provides arrays, systems, devices, methods, computer-readable media and kits that enable expression-based classification of B-precursor acute lymphoblastic leukemia (ALL) as being either responsive or non-responsive to tyrosine kinase inhibitor mono or co-therapy. | 10-30-2014 |
20140141094 | SOLID COMPOSITIONS FOR PHARMACEUTICAL USE - The invention relates to solid compositions that may be suitable for administering a therapeutic agent to a subject. The invention also relates to methods of making such solid compositions. The invention further relates to methods of treating a disease, condition, or disorder by administering to a subject such solid compositions. | 05-22-2014 |
20140079621 | Method of making magnetic iron nitride nanoparticles - Magnetic iron nitride nanoparticles, such as Fe | 03-20-2014 |
20130023773 | APPARATUS AND TECHNIQUES OF NON-INVASIVE ANALYSIS - Apparatus and methods, which comprise examination of an abnormality on a subject using a temperature stimulus applied to the subject, provide a non-invasive analysis technique. In an embodiment, a non-invasive infrared imaging technique can be used to observe the temporal response of a lesion to temperature stimuli to form a basis for evaluating the abnormality. A technique including applying temperature stimuli and detecting responses to the applied temperature stimuli provide a non-invasive technique that can be used to identify an abnormality on a subject and/or characteristics of the abnormality. In an embodiment, a non-invasive transient infrared imaging technique can be used to observe the temporal response of a lesion to temperature stimuli to form a basis for determining characteristics correlated to the lesion. Additional apparatus, systems, and methods are disclosed. | 01-24-2013 |
20130019002 | SYSTEM AND METHODS OF RESOURCE USAGE USING AN INTEROPERABLE MANAGEMENT FRAMEWORK - Generic rights expression language allowing interoperability across different computing environments including resource usage of different applications. A formal framework for usage management provides scaffolding upon which interoperable usage management systems can be built. Certain features of the framework are standardized, such as the operational semantics, including areas free of standards that necessitate choice and innovation to achieve a balance of flexibility and usability for interoperability in usage management systems. | 01-17-2013 |
20130011765 | FUEL CELL - In a fuel cell including an electrolyte layer allowing an anion component to migrate, and a fuel-side electrode and an oxygen-side electrode arranged to face each other while sandwiching the electrolyte layer, the oxygen-side electrode contains a first catalyst containing a first transition metal and polypyrrole, and a second catalyst containing a second transition metal and a porphyrin ring-containing compound so that the mixing ratio of the first catalyst relative to 100 parts by mass of the total amount of the first catalyst and the second catalyst is more than 10 parts by mass, and below 90 parts by mass. | 01-10-2013 |
20130000640 | DRY POWDER NEBULIZER - A dry powder delivery device may be configured to provide micronized dry powder particles to airways of a user. The device may include a cylindrical container delimiting a chamber containing at least one magnetically-responsive object, a motor external to said chamber, a magnet external to the chamber and rotatably coupled with the motor, and an outflow member configured to direct airflow to a user. The magnetically-responsive object may be coated with micronized dry powder particles, and the motor may be operable to rotate the magnet about an axis. Rotation of the magnet creates a magnetic field that causes the magnetically-responsive object to move in response to the magnetic field and collide with a side wall of the container to deaggregate the dry powder particles and aerosolize the dry powder in the chamber. | 01-03-2013 |
20120207913 | METHODS AND SYSTEMS FOR DOSING AND COATING INHALATION POWDERS ONTO CARRIER PARTICLES - A method of method of coating powdered medical agent onto a carrier particle for use in a dry powder inhaler may include applying ultrasonic energy to agglomerated powdered medical agent to deaggregate and aerosolize particles of the medical agent into particles having a desired average particle size, and coating at least one carrier particle with a desired amount of the deaggregated and aerosolized particles of the medical agent. | 08-16-2012 |
20120001153 | PULSED GROWTH OF CATALYST-FREE GROWTH OF GaN NANOWIRES AND APPLICATION IN GROUP III NITRIDE SEMICONDUCTOR BULK MATERIAL - Exemplary embodiments provide semiconductor devices including high-quality (i.e., defect free) group III-N nanowires and uniform group III-N nanowire arrays as well as their scalable processes for manufacturing, where the position, orientation, cross-sectional features, length and the crystallinity of each nanowire can be precisely controlled. A pulsed growth mode can be used to fabricate the disclosed group III-N nanowires and/or nanowire arrays providing a uniform length of about 10 nm to about 1000 microns with constant cross-sectional features including an exemplary diameter of about 10-1000 nm. In addition, high-quality GaN substrate structures can be formed by coalescing the plurality of GaN nanowires and/or nanowire arrays to facilitate the fabrication of visible LEDs and lasers. Furthermore, core-shell nanowire/MQW active structures can be formed by a core-shell growth on the nonpolar sidewalls of each nanowire. | 01-05-2012 |
20110286934 | MEMBRANE TRANSDUCTION PEPTIDES, POLYNUCLEOTIDES, AND METHODS - Isolated polypeptides, nucleic acids, and methods relating to cellular internalization of materials are described herein. Generally, the isolated polypeptides include a membrane transduction domain of human tissue factor pathway inhibitor-2 (TFPI-2). In some cases, the isolated polypeptide can be a fusion peptide that includes a membrane transduction domain of human TFPI-2 and a heterologous peptide domain. The nucleic acids include nucleic acids that encode the isolated polypeptides described herein. The methods generally include providing a composition that includes a membrane transduction domain of human TFPI-2 coupled to a material, and contacting the composition with a cell under conditions effective to permit the cell to internalize the composition. | 11-24-2011 |
20110092533 | COMPOUNDS FOR BINDING TO ER ALPHA/BETA AND GPR30, METHODS OF TREATING DISEASE STATES AND CONDITIONS MEDIATED THROUGH THESE RECEPTORS AND IDENTIFICATION THEREOF - The current invention is in the field of molecular biology/pharmacology and provides compounds which modulate the effects of GPR30 as well as the classical estrogen receptors alpha and beta (ERα and ERβ). These compounds may function as agonists and/or antagonists of one or more of the disclosed estrogen receptors. Diseases which are mediated through one or more of these receptors include cancer (particularly breast, reproductive and other hormone-dependent cancers, leukemia, colon cancer, prostate cancer), reproductive (genito-urological) including endometreitis, prostatitis, polycystic ovarian syndrome, bladder control, hormone-related disorders, hearing disorders, cardiovascular conditions including hot flashes and profuse sweating, hypertension, stroke, obesity, osteoporosis, hematologic diseases, vascular diseases or conditions such as venous thrombosis, atherosclerosis, among numerous others and disorders of the central and peripheral nervous system, including depression, insomnia, anxiety, multiple sclerosis, neuropathy, neurodegenerative disoders such as Parkinson's disease and Alzheimer's disease, as well as inflammatory bowel disease, Crohn's disease, coeliac (celiac) disease and related disorders of the intestine. A contraceptive indication to prevent or reduce the likelihood of pregnancy after intercourse is a further aspect of the present invention. | 04-21-2011 |
20110033380 | COMPOUNDS AND METHODS FOR USE IN DIAGNOSING AND TREATING MELANOMA, INCLUDING METASTATIC MELANOMA AND METHODS RELATED TO SAME - The present invention is directed to novel non-invasive diagnostic tools/compounds comprising a cyclic peptide wherein the compound binds to a MSH receptor to image and treat cancers, especially, melanoma, including metastatic melanoma in vivo. The present invention represents a clear advance in the art which presently relies on tissue biopsy for diagnoses of these cancers. The novel imaging probes are capable of detecting cancerous melanoma cells, as well as their metastatic spread in tissues. This represents a quantum step forward in the diagnosis and treatment of melanoma, including metastatic melanoma using non-invasive molecular imaging techniques. The novel probes of the present invention will also be useful to initiate therapy for melanoma as well as monitor patients response to chemotherapy treatments and other interventions or therapies used in the treatment of melanoma/metastatic melanoma. Compounds according to the present invention may be used as diagnostic tools for a number of conditions and diseases states as well as therapeutic agents for treating such conditions and disease states. | 02-10-2011 |
20090208493 | Compounds and methods for the selective inhibition of ABCB1, ABCC1 and ABCG2 transporters and the treatment of cancers, especially drug resistant cancers and high throughput flow cytometry assay to detect selective inhibitors - Compounds disclosed which inhibit ABCB1 transporter protein are useful for treating diseases in which ABCB1 transporter protein mediates the disease state, including numerous cancers, including hematopoietic cancers, including various leukemias, especially T-lineage acute lymphoblastic leukemia, as well as cancerous tumors, especially forms which exhibit multiple drug resistance. Pharmaceutical compositions which comprise an inhibitor of ABCB1 transporter protein and at least one additional anticancer agent, optionally in combination with a pharmaceutically acceptable carrier, additive or excipient are another aspect of the present invention. A flow cytometry based, high-throughput screening (HST) assay that quantifies ABCB1 efflux is also disclosed. Methods of identifying inhibitors of ABCB1, ABCG2 and ABCC1 transporter proteins are also disclosed. | 08-20-2009 |